Regeneron Pharmaceuticals, Inc. (REGN)
REGN moved a median of +0.11% 30 minutes after news, and +0.05% by the close. How REGN actually reacts to news — the realized, point-in-time move the market made, measured across 2,000+ labeled events over the last three years with zero look-ahead.
REGN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.01% | 49% | 1,990 |
| 30-min | +0.11% | 56% | 1,996 |
| 60-min | +0.11% | 53% | 1,996 |
| to close | +0.05% | 51% | 1,975 |
| Middle 50% of REGN reactions | -0.38% to +0.61% |
|---|---|
| Median reaction (30-min) | +0.11% |
| Measured reactions | 2,000+ |
Half of all Regeneron Pharmaceuticals, Inc. news events land between -0.38% and +0.61% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How REGN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 39 | +0.32% | 64% | +0.18% |
| Analyst downgrades | 37 | +0.14% | 57% | -0.33% |
| Coverage initiations | 36 | +0.34% | 61% | +0.47% |
| Rating reiterations | 203 | +0.00% | 50% | +0.13% |
| Price-target raises | 71 | -0.05% | 48% | +0.11% |
| Price-target cuts | 68 | +0.02% | 52% | +0.24% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how REGN ranks against every other measured name →
That’s how REGN usually reacts — get an email when it moves on news →Email me when REGN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to REGN's baseline. Nothing else.
Recent REGN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types | Press release | GlobeNewswire | -0.27% | -1.53% | |
| Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension | Press release | GlobeNewswire | -0.18% | -0.34% | |
| Form 8-K REGENERON PHARMACEUTICAL For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | -0.37% | +0.56% | |
| Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026 | Press release | GlobeNewswire | -0.37% | +0.56% | |
| Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss | Press release | GlobeNewswire | +0.01% | +0.12% | |
| Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies | Press release | GlobeNewswire | +0.81% | -4.14% | |
| Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC) | Press release | GlobeNewswire | +0.27% | +0.11% | |
| Form 8-K REGENERON PHARMACEUTICAL For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | +0.81% | -4.14% | |
| Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026 | Press release | GlobeNewswire | -1.41% | -1.97% | |
| REGN DEADLINE - FINAL REMINDER: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Regeneron Pharmaceuticals, Inc. to Contact the Firm Today! | Press release | ACCESS Newswire | -0.72% | +0.22% | |
| Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN | Press release | PR Newswire | -0.02% | -0.20% | |
| Form N-PX REGENERON PHARMACEUTICAL For: Jun 30 | SEC filing · Form N-PX | SEC EDGAR | -0.02% | -0.20% | |
| Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP) | Press release | GlobeNewswire | +0.09% | +0.17% | |
| Regeneron Announces Investor Conference Presentations | Press release | GlobeNewswire | +0.55% | -0.61% | |
| Form 13F-HR REGENERON PHARMACEUTICAL For: Jun 30 | SEC filing · Form 13F-HR | SEC EDGAR | +0.95% | — | |
| Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN | Press release | PR Newswire | -0.37% | -1.34% | |
| Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation | Press release | GlobeNewswire | +1.26% | +4.95% | |
| Form 10-Q REGENERON PHARMACEUTICAL For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.12% | +5.48% | |
| Form 8-K REGENERON PHARMACEUTICAL For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | +0.12% | +5.48% | |
| Regeneron Reports Second Quarter 2026 Financial and Operating Results | Press release | GlobeNewswire | +0.12% | +5.48% | |
| $REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials – Investors Notified to Contact BFA Law | Press release | GlobeNewswire | -0.64% | -0.35% | |
| Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN | Press release | PR Newswire | -0.29% | -0.38% | |
| Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REGN | Press release | Business Wire | -0.29% | -0.38% | |
| Form 8-K REGENERON PHARMACEUTICAL For: Jul 06 | SEC filing · Form 8-K | SEC EDGAR | -0.14% | +0.12% | |
| Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast | Press release | GlobeNewswire | +1.14% | +1.49% | |
| Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG) | Press release | GlobeNewswire | -0.97% | +1.33% | |
| Form 8-K REGENERON PHARMACEUTICAL For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | -0.68% | -0.35% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.06% | -0.01% | |
| Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO | Press release | GlobeNewswire | -0.12% | +0.10% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Regeneron Pharmaceuticals, Inc. (REGN) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.23% | +0.64% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Regeneron Pharmaceuticals, Inc. (REGN) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.18% | +0.91% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Regeneron Pharmaceuticals, Inc. (REGN) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.13% | -0.65% | |
| Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.10% | -0.88% | |
| Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak | Press release | GlobeNewswire | -0.03% | -0.86% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Regeneron Pharmaceuticals, Inc. (REGN) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.14% | -0.18% | |
| Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.21% | -1.00% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.18% | -1.22% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.18% | -1.22% | |
| Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss | Press release | GlobeNewswire | +0.35% | +0.18% | |
| Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis | Press release | GlobeNewswire | +0.35% | +0.18% | |
| REGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law Violations | Press release | PR Newswire | -1.84% | -0.03% | |
| Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas | Press release | GlobeNewswire | -0.66% | +2.23% | |
| Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair | Press release | GlobeNewswire | -0.00% | +0.07% | |
| Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma | Press release | GlobeNewswire | -0.66% | +2.23% | |
| UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair | Press release | GlobeNewswire | -0.66% | +2.23% | |
| Form 13F-HR REGENERON PHARMACEUTICAL For: Mar 31 | SEC filing · Form 13F-HR | SEC EDGAR | +1.54% | -0.31% | |
| Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years | Press release | GlobeNewswire | +0.34% | +0.79% | |
| Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial | Press release | GlobeNewswire | +0.34% | -1.19% | |
| Form 10-Q REGENERON PHARMACEUTICAL For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.36% | -2.37% | |
| Form 8-K REGENERON PHARMACEUTICAL For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | -0.36% | -2.37% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the REGN section they belong to.
Where else REGN is measured.
REGN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| DexCom, Inc. (DXCM) | 2,000+ | +0.04% | 51% |
| Endo International plc - Ordinary Shares (ENDP) | 2,000+ | 0.00% | 49% |
| Novo Nordisk A/S (NVO) | 1,909 | 0.00% | 50% |
| CELGENE (CELG) | 1,880 | +0.03% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Regeneron Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled REGN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 2,000+ events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 56% of REGN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does REGN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.